The global precision medicine market size is calculated at USD 119.03 billion in 2025 and is predicted to reach around USD 470.53 billion by 2034, accelerating at a CAGR of 16.50% from 2025 to 2034. The North America precision medicine market size surpassed USD 55.17 billion in 2024 and is expanding at a CAGR of 16.52% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
7.1. Precision Medicine Market, by Technology Type
7.1.1. Bioinformatics
7.1.1.1. Market Revenue and Forecast
7.1.2. Big Data Analytics
7.1.2.1. Market Revenue and Forecast
7.1.3. Drug Discovery
7.1.3.1. Market Revenue and Forecast
7.1.4. Gene Sequencing
7.1.4.1. Market Revenue and Forecast
7.1.5. Companion Diagnostics
7.1.5.1. Market Revenue and Forecast
7.1.6. Others
7.1.6.1. Market Revenue and Forecast
8.1. Precision Medicine Market, by Application
8.1.1. CNS
8.1.1.1. Market Revenue and Forecast
8.1.2. Immunology
8.1.2.1. Market Revenue and Forecast
8.1.3. Oncology
8.1.3.1. Market Revenue and Forecast
8.1.4. Respiratory
8.1.4.1. Market Revenue and Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Forecast
9.1. Precision Medicine Market, by End-Use
9.1.1. Diagnostic Companies
9.1.1.1. Market Revenue and Forecast
9.1.2. Pharmaceutical Companies
9.1.2.1. Market Revenue and Forecast
9.1.3. Healthcare IT companies
9.1.3.1. Market Revenue and Forecast
9.1.4. Others
9.1.4.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Technology
10.1.2. Market Revenue and Forecast, by Application
10.1.3. Market Revenue and Forecast, by End-Use
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Technology
10.1.4.2. Market Revenue and Forecast, by Application
10.1.4.3. Market Revenue and Forecast, by End-Use
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Technology
10.1.5.2. Market Revenue and Forecast, by Application
10.1.5.3. Market Revenue and Forecast, by End-Use
10.2. Europe
10.2.1. Market Revenue and Forecast, by Technology
10.2.2. Market Revenue and Forecast, by Application
10.2.3. Market Revenue and Forecast, by End-Use
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Technology
10.2.4.2. Market Revenue and Forecast, by Application
10.2.4.3. Market Revenue and Forecast, by End-Use
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Technology
10.2.5.2. Market Revenue and Forecast, by Application
10.2.5.3. Market Revenue and Forecast, by End-Use
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Technology
10.2.6.2. Market Revenue and Forecast, by Application
10.2.6.3. Market Revenue and Forecast, by End-Use
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Technology
10.2.7.2. Market Revenue and Forecast, by Application
10.2.7.3. Market Revenue and Forecast, by End-Use
10.3. APAC
10.3.1. Market Revenue and Forecast, by Technology
10.3.2. Market Revenue and Forecast, by Application
10.3.3. Market Revenue and Forecast, by End-Use
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Technology
10.3.4.2. Market Revenue and Forecast, by Application
10.3.4.3. Market Revenue and Forecast, by End-Use
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Technology
10.3.5.2. Market Revenue and Forecast, by Application
10.3.5.3. Market Revenue and Forecast, by End-Use
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Technology
10.3.6.2. Market Revenue and Forecast, by Application
10.3.6.3. Market Revenue and Forecast, by End-Use
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Technology
10.3.7.2. Market Revenue and Forecast, by Application
10.3.7.3. Market Revenue and Forecast, by End-Use
10.4. MEA
10.4.1. Market Revenue and Forecast, by Technology
10.4.2. Market Revenue and Forecast, by Application
10.4.3. Market Revenue and Forecast, by End-Use
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Technology
10.4.4.2. Market Revenue and Forecast, by Application
10.4.4.3. Market Revenue and Forecast, by End-Use
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Technology
10.4.5.2. Market Revenue and Forecast, by Application
10.4.5.3. Market Revenue and Forecast, by End-Use
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Technology
10.4.6.2. Market Revenue and Forecast, by Application
10.4.6.3. Market Revenue and Forecast, by End-Use
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Technology
10.4.7.2. Market Revenue and Forecast, by Application
10.4.7.3. Market Revenue and Forecast, by End-Use
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Technology
10.5.2. Market Revenue and Forecast, by Application
10.5.3. Market Revenue and Forecast, by End-Use
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Technology
10.5.4.2. Market Revenue and Forecast, by Application
10.5.4.3. Market Revenue and Forecast, by End-Use
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Technology
10.5.5.2. Market Revenue and Forecast, by Application
10.5.5.3. Market Revenue and Forecast, by End-Use
11.1. Biocrates Life Sciences
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Tepnel Pharma Services
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Novartis
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Qiagen
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Quest Diagnostics
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Menarini Silicon Biosystems
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. NanoString Technologies
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Eagle Genomics
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Pfizer
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Intomics
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. Roche
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. Teva Pharmaceutical
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample